Bank of New York Mellon
BOLT icon

Bank of New York Mellon’s Bolt Biotherapeutics BOLT Stock Holding History

Bank of New York Mellon’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-629
Closed -$16.1K – 4350
2023
Q2 		$16.1K Sell
629
-2
-0.3% -$63 ﹤0.01% 4308
2023
Q1 		$17.6K Hold
631
– – ﹤0.01% 4318
2022
Q4 		$16.4K Sell
631
-3
-0.5% -$82 ﹤0.01% 4375
2022
Q3 		$19K Sell
634
-9
-1% -$372 ﹤0.01% 4456
2022
Q2 		$26K Sell
643
-3,922
-86% -$152K ﹤0.01% 4464
2022
Q1 		$249K Buy
4,565
+524
+13% +$35.3K ﹤0.01% 4119
2021
Q4 		$397K Buy
4,041
+511
+14% +$97K ﹤0.01% 3942
2021
Q3 		$893K Buy
3,530
+1,199
+51% +$339K ﹤0.01% 3450
2021
Q2 		$721K Buy
2,331
+727
+45% +$295K ﹤0.01% 3595
2021
Q1 		$1.05M Buy
+1,604
New +$1.04M ﹤0.01% 3301

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon's BOLT Position: Q3 2023 in Review

Bank of New York Mellon sold out of Bolt Biotherapeutics (BOLT) in Q3 2023, closing a stake of 629 shares — an estimated $16.1K sold.

Bank of New York Mellon first reported a position in BOLT in Q1 2021 and held it in 10 quarters. The position peaked at $1.05M in Q1 2021. 34 funds tracked by Wall St. Rank hold BOLT as of Q3 2023.

  • Bank of New York Mellon reported no remaining Bolt Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 629 Bolt Biotherapeutics shares in Q3 2023, an estimated $16.1K.
  • Bank of New York Mellon first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • Bank of New York Mellon's Bolt Biotherapeutics position peaked at $1.05M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2023.

Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.